Bicycle Therapeutics PLC
(NAS:BCYC)
$
23.4
-0.9 (-3.7%)
Market Cap: 1.62 Bil
Enterprise Value: 802.88 Mil
PE Ratio: 0
PB Ratio: 1.95
GF Score: 77/100 Bicycle Therapeutics PLC at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023 / 02:10PM GMT
Release Date Price:
$21.17
(-7.27%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
(technical difficulty) Morgan Stanley Global Healthcare conference, I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Bicycle Therapeutics with CEO, Kevin Lee; Chief Development Officer, Santiago Arroyo; Head of Commercial, Jennifer Perry. Welcome.
Kevin Lee
Bicycle Therapeutics plc - Director
Thanks. Good to be here.
Questions & Answers
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
So for those who may not be familiar with Bicycle, can you provide a brief introduction?
Kevin Lee
Bicycle Therapeutics plc - Director
Sure. Bicycle is a company that works on a
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot